Here’s a slightly older bulletin.
An interesting product, which has been found to be effective and cost-efficient in studies, and is even mentioned in the aforementioned treatment recommendations. It’s an easy-to-use device for clinicians, and in addition to device sales, there’s additional revenue from patient-specific parts/covers. So, there should be potential.
But… sales revenue should start coming in so that they don’t run out of money and need a new share issue.